Quick Facts

Роксан (Roxithromycin) is a medication used to address various infections caused by susceptible bacteria. It works to manage symptoms associated with bacterial growth.

This medicine supports the body in resolving infections across several therapeutic domains. Роксан is typically used for the treatment of susceptible bacterial infections in the respiratory tract, which may include conditions affecting the throat, lungs, or nasal passages. It is also indicated for managing certain ear and skin infections where bacterial causes have been identified. Additionally, Роксан may be used to manage some genitourinary tract infections and soft tissue infections.

Use of this medication should always be reserved for bacterial causes and is a component of a clinical management plan as determined by a healthcare provider. The medication has an established spectrum of therapeutic application.

Eligibility Map: Who can and cannot use Роксан — official regulatory information

Age-related and Organ Function Eligibility Rules

Use is established for adults and for children with approved indications, provided use adheres to official, weight-based dosing thresholds. The medicine is restricted and requires dosage modification for patients with impaired renal function that is not severe, due to the drug’s primary renal excretion. Use is also restricted and requires caution in patients with impaired hepatic function, particularly those with liver cirrhosis.

Pregnancy and Lactation Eligibility Status

Use during pregnancy and lactation is generally not recommended and is restricted to cases where the clinical benefit is determined to outweigh the potential risk, necessitating prior consultation.

Connection to the overall eligibility profile

The regulatory documents define the eligibility profile of Роксан primarily through exclusionary criteria related to severe organ function and known patient sensitivities. Use is established for the majority of the population (adults and specific pediatric weight groups) provided they do not possess these documented contraindications or organ function limitations which necessitate restricted use or close monitoring.

Interactions with other medicines and products

Interactions with other medicinal products and products are documented in regulatory labeling and are generally classified based on their potential to alter drug concentrations or enhance specific effects.

Interaction Scope

Official Interaction Statements and Constraints

• P-gp Substrates: Concomitant use with P-gp substrates may lead to increased exposure and higher systemic concentrations of the co-administered drug, necessitating cautious administration and monitoring.
• CNS Depressants: Combined use with alcohol or other CNS depressants significantly enhances the risk of profound sedation, respiratory depression, coma, and death. The use of these combinations must be approached with extreme caution, often requiring reduced dosages.
• MAO Inhibitors: Monoamine Oxidase Inhibitors (MAOIs) can potentiate the action of certain opioid agents, and this combination may be highly clinically significant and generally avoided.
• Anticoagulants: The risk of bleeding and hemorrhage is increased when combined with anticoagulant or antiplatelet agents. Patients must be carefully monitored for signs of hemorrhage, especially with prolonged use.

Connection to the Overall Interaction Profile

Regulatory documentation defines the interaction structure primarily around pharmacokinetic mechanisms, such as P-gp inhibition leading to concentration increases, and pharmacodynamic enhancement, which involves additive CNS depressant effects. The official profile mandates specific caution or avoidance for combinations that significantly raise the risk of respiratory compromise or enhance the systemic exposure of sensitive co-administered medicines.

Роксан acts as a synthetic mu-opioid receptor agonist within the central nervous system (CNS) and on smooth muscle containing these receptors. The primary molecular interaction involves the binding of the molecule to the mu-opioid receptor, a G-protein-coupled receptor (GPCR). This binding event activates inhibitory G-proteins, specifically initiating the dissociation of the Gbetagamma subunit from the Galpha subunit. The active G-protein complex subsequently inhibits the enzyme adenylate cyclase, resulting in a decrease in the intracellular concentration of the second messenger cyclic adenosine monophosphate (cAMP). Simultaneously, G-protein activation promotes the efflux of potassium ions through specific voltage-gated potassium channels. This increased potassium conductance causes neuronal hyperpolarization and a subsequent reduction in neuronal excitability and decreased release of various excitatory neurotransmitters from the presynaptic terminal. This modulation of neurotransmission results in system-level alteration of signal propagation in the central nervous system and smooth muscle structures.

The administration of Роксан (Roxithromycin) follows a standardized protocol. The medicine is strictly for oral use and is supplied in forms such as the 150 mg and 300 mg film-coated tablets. Standard adult use is structured around achieving a 300 mg daily dose, which may be administered through one of two primary regimens: either a single 300 mg tablet once daily or a divided dose of 150 mg taken twice daily (every 12 hours).

For optimal absorption, the administration of the tablet must occur on an empty stomach or specifically 15 minutes before a meal, swallowed whole with a drink. The duration of the treatment course varies but is typically 5 to 10 days; however, a course of at least 10 days is typically indicated for streptococcal throat infections.

Dose adjustments are specified for certain populations. Patients with severe hepatic impairment (cirrhosis) require a reduction to a 150 mg dose taken once daily. In pediatric patients, the dose for those under 40 kg is calculated based on weight (5 to 8 mg/kg/day in two divided doses), and the treatment duration for children should not exceed 10 days. No dosage change is typically required for older adults or patients with renal impairment, and if a dose is missed, it should be taken when remembered, but never doubled to compensate for the skipped dose.

The research available for Роксан, a medicine containing the active substance Roxatidine, focuses primarily on its function as a histamine H₂-receptor antagonist. Research explored the drug's activity in conditions associated with excessive stomach acid. The overall research base relies on findings from government-reviewed clinical trials and published scientific analyses.

The most extensive body of evidence exists for Acute Peptic Ulcer Disease. Research includes numerous short-term, randomized controlled trials (RCTs) for adults diagnosed with active duodenal and benign gastric ulcers. These studies were often double-blind and monitored the endoscopic ulcer healing rate and measured outcomes related to physical discomfort. Studies reported measurements of healing rates that were observed in relation to those of the active H₂-blocker comparator groups. While this acute evidence base is extensive, the follow-up durations were limited.

For Long-Term Studies and Maintenance Treatment, research explored symptom patterns in patient populations observed following the healing of a previous ulcer. These long-term trials monitored the rate of ulcer relapse or recurrence over intervals up to twelve months to evaluate long-term patterns.

Research also explored outcomes in conditions characterized by fluctuating manifestations, such as Gastro-oesophageal Reflux Disease (GORD). Studies monitored physiological strain, specifically the effect on intragastric pH (acidity levels). Scientific reviews note that certainty remains low, and data limitations suggest a need for broader clinical observation in this therapeutic area. The majority of the available research focused on adult patients enrolled in the initial clinical trials; data for certain groups, such as children or patients with specific severe comorbid conditions, remain insufficient. Evidence quality varies across studies for different indications, and long-term effects are not fully established.

Common questions about Роксан (FAQ)

Q: How quickly can a person generally expect Роксан to start working for its intended purpose?

A: Official information derived from pharmacokinetic data indicates that the active effect of the medicine typically begins within about one hour after it is taken. The maximum level of acid reduction generally occurs within one to three hours of administration.

Q: Is it normal to feel a bit nauseous when first starting Роксан?

A: Regulatory documents classify nausea as a common adverse reaction, which means it is one of the effects most frequently reported in clinical data and listed on the product label. This is a documented experience associated with the medicine.

Q: Does Роксан interact with alcoholic beverages?

A: While the active ingredient, Roxatidine, is not known to have a direct pharmacological interaction with alcohol, official information suggests that alcohol can stimulate stomach acid production. Because the medicine is intended to reduce acid, official resources note that alcohol consumption could counteract the therapeutic goal.

Q: What are the signs of a potential serious side effect that would require immediate medical attention?

A: Official safety information highlights signs of a severe allergic reaction as those requiring immediate medical attention. These can include a sudden onset of hives, widespread rash, difficulty breathing or swallowing, or swelling of the face, tongue, or throat. These signs are documented in official safety information as those requiring immediate medical attention.

Q: Can Роксан be used during pregnancy or while breastfeeding, according to regulatory guidelines?

A: Official documents generally state that data on human use during pregnancy and breastfeeding are limited. Consultation is therefore required, as official guidance stipulates use only when the clinical benefit is judged to outweigh the potential risk.

Q: Are there any specific organs, like the liver or kidneys, that are commonly mentioned in safety information about Роксан?

A: Yes, official safety information includes specific precautions and warnings related to the kidneys (renal function) and the liver. This is because the medicine is primarily eliminated through the urine and metabolized by the liver, necessitating careful consideration for patients with pre-existing organ impairment.

Q: Is it possible to take Роксан if a person has a history of liver problems?

A: Regulatory documents state that precaution should be taken for patients with underlying liver disease, as the medicine is metabolized in the liver. Furthermore, use is contraindicated (advised against) in cases of severe hepatic impairment.

Q: Why is Роксан sometimes prescribed when a person does not have the most severe form of the condition?

A: Studies and research summaries indicate the medicine is used for a range of acid-related conditions beyond just actively bleeding or severe ulcers. It is also used for maintenance treatment or long-term regimens to help prevent the recurrence or return of ulcers that have previously healed.

Q: Can Роксан affect a person's ability to drive or operate machinery?

A: Safety documents generally indicate that there is no specific known drug-related interaction that directly impairs driving. However, side effects may include symptoms like drowsiness or dizziness, which are listed as potential effects that could temporarily affect a person's ability to perform complex tasks.

Q: Is Роксан a medicine that needs to be taken indefinitely?

A: The duration of use is determined by the specific condition being addressed. While short courses treat acute issues, official research also supports extended-use regimens for maintenance treatment.

Q: What happens if Роксан is taken with certain types of antacids?

A: To ensure effective action, regulatory-aligned advice suggests separating the intake of antacids from the dose of this medicine. Official guidance typically references a period of 2 hours before or 2 hours after.

Q: Can Роксан affect a person's sleep or cause changes like insomnia or vivid dreams?

A: Official safety information lists sleep disturbance and restlessness as potential side effects of the medicine. These are effects on the nervous system that may impact a person's ability to sleep.

Q: Is Роксан used to prevent health issues, or only to treat existing conditions?

A: Official research and drug information confirm that the medicine is used for both treating existing conditions (like active ulcers) and for preventative purposes, specifically as a maintenance therapy to reduce the risk of ulcer recurrence.

Q: Can taking Роксан cause joint pain?

A: Official safety documents list muscle pain (myalgia) as a potential side effect. Specific mentions of joint pain (arthralgia) are less consistent across primary summaries than the documented muscle pain (myalgia).

Q: Is it necessary to follow a special diet while taking Роксан?

A: While a strict 'special diet' is not mandated, advice aligned with official sources often suggests avoiding substances that can irritate the stomach and increase acid secretion. This includes alcohol and certain acidic drinks like soft drinks or citrus juices, which could work against the medicine's therapeutic goal.

Q: Does the medicine contain any ingredients a person might be allergic to?

A: Yes, official labeling states the medicine is advised against (contraindicated) in patients with a known history of hypersensitivity to the active ingredient, Roxatidine acetate, or to any other component of the formulation. The full list of components is available in the product's official information.

Q: Is there a risk of memory loss or confusion associated with Роксан?

A: Official safety information lists side effects that can include confusion. While specific mention of permanent memory loss is not standard, the potential for other central nervous system effects is documented.

Q: How long does the effect of one dose of Роксан generally last?

A: According to official-aligned information, the duration of the acid-reducing effect of a single dose of this medicine typically lasts for about 10 to 12 hours.

Q: What are the known interactions between Роксан and HIV or Hepatitis C medications?

A: Regulatory-aligned resources state that taking the medicine with certain HIV treatments, such as those containing elvitegravir/cobicistat, is considered unlikely to cause a clinically significant interaction, and no dose change is usually needed for the HIV medicine.

Q: Is there an expectation for how much a person's condition might improve while on Роксан?

A: Clinical trials provide data points on treatment results. For instance, research on duodenal ulcers reported a specific healing effectiveness of 78.9% after four weeks of treatment.

Q: Is Роксан used for more than one type of related condition?

A: Yes, official documents indicate the medicine is used for multiple acid-related conditions. These include treating gastric ulcer, duodenal ulcer, and gastroesophageal reflux disease (GERD).

Q: Do official documents mention a maximum duration for taking Роксан?

A: Official guidance often indicates that over-the-counter use of this medicine is typically limited to a period of up to two weeks. Use beyond this period may require professional reassessment.

The storage and disposal of Роксан (Roxithromycin) must strictly follow the conditions specified in official regulatory documents to ensure product stability.

Official Storage Requirements

Disposal Instructions

Official disposal guidance states that unused or expired medicine should be returned to a pharmacy or official collection point for safe disposal. It is required that the product not be thrown into household waste or flushed down the toilet to avoid environmental contamination, unless specifically instructed by local regulators.